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Abstract
Background: Retention studies are usually focused on patients on antiretroviral treatment (ART), however in Sub-Saharan
Africa many patients get lost to program (LTP) in the pre-ART care period.. We investigated the proportion of patients not
retained in care and factors associated with LTP (dead or lost to follow up ≥6 months) in the pre-ART care period.
Methods: We analyzed data from the Infectious Diseases Institute, Kampala, Uganda. We included all adult patients
≥18 years, ART naïve at program enrollment from 1st/Jan/2005. We described the number of patients not retained
in care during the 3 steps of enrollment-to-treatment “cascade”: Step 1) From enrollment to CD4 count testing,
Step 2) ART eligibility assessment. Patients were initially considered eligible if CD4 count was <200 cell/μL, and
<350 cell/μL from 2012 onwards; Step 3) From eligibility to ART start. We described cumulative probability of being
LTP by gender and ART eligibility using Kaplan Meier estimates. We used a Cox proportional hazards model to
identify factors associated with being LTP at any stage for all patients and for those with a CD4 count available.
Factors considered were age, gender, year of enrollment, and WHO stage.
Results and discussion: After enrollment in our program, cumulatively, a low proportion of patients (30.8 %) were
retained and started on ART. The cumulative probability of being LTP was higher in males and patients not eligible
for ART. In the multivariable Cox proportional Hazards model, male gender (HR: 1.19 CI 1.12-1.19) and clinical WHO
stage 3 and 4 (HR: 1.20 CI 1.13-1.27) were associated with being LTP while older age was protective (HR: 0.98
0.96-0.99). Patients enrolled in the program more recently were also at lower risk of being LTP. In addition,
among patients with CD4 count test, patients with higher CD4 count were at higher risk of being LTP.
Conclusions: In our program there has been suboptimal retention of patients in pre-ART care, particularly of
patients not eligible for ART. Since the proportion of eligible patients has recently increased due to the higher
recommended threshold for ART eligibility (CD4 count > 500 cell/μL in 2014), this could lead to an increase in
program retention as more people fall under the recommended threshold and seek care.
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Background
Lost to follow up studies are usually focused on patients
on antiretroviral treatment (ART). However in Sub-
Saharan Africa many patients get lost in the pre-ART
care period, when they are expected to attend visits for
ART screening which involve CD4 count testing and
assessment for ART eligibility. The cascade from HIV
testing to treatment usually consists of three steps: Step
I: enrollment in care and CD4 count measurement, step
II: assessment for ART eligibility, and step III: ART start
[1]. Typically in Sub-Saharan African HIV care pro-
grams, it takes between 1–3 months to ensure patients
are ready to initiate ART [2]. During this period, patients
are counseled on ART readiness, adherence and on
other informed about important aspects of ART such as
toxicity and side effects.
Reviews published from resource-limited settings [1–4]
and Sub-Saharan Africa in particular, show dropout rates
of individuals who test HIV positive before ART initiation
varying between 15 % and 60 % [1–3, 5]. In resource-
limited settings where there are limited or incomplete
national death registries, it is difficult to confirm whether
patients who drop out are dead. In such large HIV care* Correspondence: bcastelnuovo@idi.co.ug
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programs, there are limited resources to actively track pa-
tients who drop out of care especially prior to ART start.
In addition, ART delivery has been rapidly decentralized
however systems have not been put in place to efficiently
transfer patients or to trace patients who migrate through
different programs, and therefore the magnitude of patient
lost to follow up could be overestimated [6].
In this study we sought to investigate the proportion of
patients not retained in the program and attempted to re-
port the reason for attrition during 9 years of offering care
and treatment to HIV positive individuals, and investigated
factors associated with being lost to program.
Methods
Study setting
The Infectious Diseases Institute (IDI), Makerere Uni-
versity, is an HIV center of excellence [7] located in
Mulago referral Hospital in Kampala. IDI is one of the
first HIV care and treatment organizations in Uganda;
the IDI clinic began providing HIV care in 2002, while
free antiretroviral treatment has been provided since
April 2004. Similarly to other programs in the region
[8], patients are assessed for ART eligibility and they are
expected to attend at least two counseling session in
order to be prepared to start ART.
Study population
In this analysis we included all patients ≥18 years and
ART naïve at enrollment in the IDI clinic from the 1st of
January 2005 to December 2013. We described the num-
ber of patients who were not retained and the reason for
attrition (lost to follow-up, death or transferred to an-
other program) during these 3 steps of enrollment-to-
treatment “cascade”: 1) From enrollment to CD4 count
testing, 2) ART eligibility assessment (patients who re-
ceived their CD4 count at the following clinic visit).
Fig. 1 Patients retained and lost to program in the cascade from program enrollment to ART initiation
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Patients were considered eligible for ART initiation ac-
cording to the WHO guidelines adopted in the country:
CD4 count <200 cell/μL [9] from 2005 to 2011 and <350
cell/μL in the 2012–2013 period [10]; 3) From ART eli-
gibility to ART initiation.
Ascertainment of outcomes
Up to 2011 ascertainment of outcomes of patients who
missed clinic visits was not systematically performed; since
2011 ascertainment of patients’ outcomes has been ongoing
and several attempts are often made (up to three times) to
contact patients (and/or their next of kin) by phone call.
However often phone contacts are not available or up to
date. Patients were defined as lost to follow up (LTFU) if
they do not return to the clinic for at least 6 months and
they were known to be alive and disengaged from care, or if
the outcome unascertainable. From June 2011, upon pa-
tients’ request or following the providers’ advice, patients
were transferred out to other HIV care facilities through a
structured process. This process involved counseling and
provision of a referral form to be delivered to the future
HIV care providers containing all the relevant health infor-
mation. It is however possible that some patients transfer
themselves without informing the providers.
Statistical analysis
In the survival analysis, time at risk was calculated as
the difference between date of enrolment and the
*
*
A
B
Fig. 2 Cumulative probability of being LTP a by gender b by CD4 count *
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following dates; Step 1: date of death (if died), or ran-
domly assigned date within two weeks from enrolment
or next scheduled appointment date when CD4 testing
should have occurred; Step 2: date of CD4 blood draw;
Step 3: date of last visit prior to ART initiation for pa-
tients eligible and started ART, while the date of last
pre-ART visit or database closure (25th July 2014) for the
patients who were eligible but had not yet started ART,
whichever came first. For the patients not eligible for
ART, again the date of last pre-ART visit or database
closure whichever came first for the patients who were
retained in care, and date of ART eligibility assessment
for the patients who were not retained in care. The def-
inition of lost to program (LTP) included patients who
were either dead or lost to follow-up, but excluded those
who transferred out of care in the pre-ART care period.
All patients who were transferred out were censored at
the date of transfer. We described time from enrollment
to CD4 count testing and later time to ART start and cu-
mulative probability of being LTP by gender and ART
eligibility using Kaplan Meier estimates.
We used a Cox proportional hazards model to identify
factors associated with being LTP at any of the stages in
the enrollment-to-treatment cascade. Factors considered
were age, gender, year of enrollment in IDI (year 2008 was
identified as the beginning of the rapid decentralization of
HIV services in Uganda), WHO clinical stage. We per-
formed a subgroup analysis that included only patients with
a CD4 count measurement, and sought to identify time to
CD4 cell count testing, as well as predictors of LTP. Miss-
ing data was observed on WHO clinical stage and multiple
imputation using chained equations, with five rounds and
was used to fill in the missing data. All analysis was per-
formed using STATA corp 12.2, Texas, USA.
The protocol for the use of retrospective use of data
routinely collected in IDI was reviewed and approved by
the Makerere University Faculty of Medicine Research
and Ethics Committee (approval number: 120–2009)
and the Uganda National Council for Science and Tech-
nology (approval number: HS 683). According to the
protocol procedures patients do not provide verbal or
written consent, but all their information is analyzed
after stripping it of unique personal identifiers.
Results and Discussion
Of a total of 19,774 patients enrolled in the IDI program
between January 2005 to December 2013, 12,926 (65 %)
were female, the median age was 33 years (interquartile
range (IQR): 27–39), and 42 % were in WHO clinical
stage III and IV. Fig. 1 shows in detail the number and
proportion of patients retained in care at IDI and the
reason for attrition during the 3 steps of the enrollment-
to- treatment cascade.
Overall of the 19,774 patients, 2,717 (13.7 %) never
had a CD4 count test (Step1), of which 10.8 % were
LTP; of the 17,057 retained who achieved a CD4 count
test, 948 (5.8 %) did not return and therefore were not
assessed for ART eligibility (Step 2). Of the 16,109
assessed for ART 7,606 (46 %) were eligible for initi-
ation, and of these 6,099 (80.2 %) were started on ART,
while the remaining patients were LTP before ART start.
Overall after enrollment in our program a low propor-
tion of patients (30.8 %) were retained and started on
ART. The median time from enrollment to CD4 count
Table 1 Factors associated with lost to program after enrolment into HIV care
All patients 1 Patients with CD4 count test
performed 2 (N = 17057)(N = 19774)
Variable Crude HR (95 % CI) P-value AHR 95 % (CI) P-value
Females 1.00 1.00
Males 1.19 (1.12 – 1.26) <0.001 1.23 (1.15– 1.31) <0.001
Age, 5 year increase 0.98 (0.96 – 0.99) 0.006 0.99 (0.97– 1.00) 0.183
WHO Stagea I-II 1.00 1.00
III-IV 1.20 (1.13 – 1.27) <0.001 1.29 (1.21 – 1.38) <0.001
Year of enrolment
2005 - 2008 1.00 1.00
2009 - 2011 0.70 (0.64 – 0.75) <0.001 1.71 (0.65 – 0.77) <0.001
2012 - 2013 0.39 (0.31 – 0.52) <0.001 0.19 (0.12 – 0.29) <0.001
CD4 count 50 cell/μL increase N/A 1.03 (1.02 – 1.03) <0.001
1 -Predictor of LTP at any stage from enrolment into care for all patients
2 -Predictor of LTP at any stage from enrolment into care among patients with CD4 count test performed
a. 2120 patients with missing data on WHO clinical stage
N/A: not applicable
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testing was 25 days (IQR: 0–35) and from eligibility as-
sessment to ART initiation was 56 days (IQR: 36–112).
The overall cumulative probability of being LTP was
21 % (95 % CI: 20 % - 22 %) after 1 year, 30 % (95 % CI:
29 % - 31 %) after 3 years, and 35 % (95 % CI: 34 % - 36 %)
after 5 years from enrolment into care. The cumulative
probabilities of being LTP after 5 years was higher among
males compared to females 38 % (95 % CI: 37 - 40 %), ver-
sus 33 % (95 % CI: 32 % - 34 %), P < 0.001 Fig. 2a, and was
higher among patients not eligible for ART compared to
patients eligible 36 % (95 % CI: 34 % - 37 %) versus 19 %
(95 % CI: 18 %-20 %), P < 0.001 Fig. 2b.
In the multivariable Cox proportional Hazards model,
male gender (HR: 1.19, 95 % CI: 1.12-1.19) and clinical
WHO stage 3 and 4 (HR: 1.20, 95 % CI: 1.13-1.27) were
associated with being LTP, while older age was protective
(HR: 0.98, 95 % CI: 0.96-0.99 per 5 years increase). Pa-
tients recently enrolled in the IDI program had a lower
risk of being LTP (Table 1).
Among patients with CD4 count test assessment, fac-
tors associated with being LTP were similar (except for
older age which was no longer protective): in addition
patients with higher CD4 count were more likely to be
LTP with an HR of 1.03 (95 % CI 1.02 – 1.03) per 50
cell/μL increase.
Discussion
As found in other studies from Sub-Saharan Africa [1]
male patients and patients who are less symptomatic or
do not immediately receive ART are more likely to get
LTP, probably due to their perceived low risk of AIDS. A
substantial proportion of patients not retained in care,
especially in the most recent years, is explained by the
rapid decentralization of ART services in Uganda started
in 2008, when ART was made available in all districts
and at lower level facilities and many patients were
transferred to clinics closer to their residence or place of
work; therefore the exit from the cascade within our
program may not necessarily reflect an equivalent pro-
portions of patients from the overall cascade from HIV
diagnosis to ART start [11].
The overall mortality particularly in patients eligible
for ART (6.7 %) is lower, likely due to underestimation,
than previously reported rates from routine programs in
Uganda (28 % - 37 %) where patients were actively
tracked and visited at home following disengagement
from care [5, 12]. Furthermore, the availability of point
of care CD4 count testing services could have led to re-
duction in the proportion of patients LTP at Step 1 of
the cascade [13]. In our program however, patients were
assessed and initiated on ART in a relatively short time
period (ART eligibility within a month and ART initi-
ation within 2 months from enrollment), and the great-
est risk LTP was observed among patients who were not
eligible for ART and therefore after receiving a CD4
count test (Step 2).
Conclusions
In our program, routine tracing of patients who missed
their clinic appointments was implemented in 2011. This
could have made an impact in reducing pre-ART lost to
care. Where feasible patients lost to program should be
actively tracked and health information systems used to
monitor patients’ migration between facilities so to avoid
overestimation of the number of patients LTP. Since
healthier patients are at higher risk of getting LTP, it is
imperative that emphasis is given in training health
workers to efficiently deliver motivation messages and to
enhance health-seeking behavior. In our program pa-
tients eligible for ART are referred for ART preparation
counseling, while those not eligible are simply given a
follow up clinic appointment. Programs should consider
referring as well patients not eligible for ART to post
CD4 count assessment counseling in order to emphasize
the importance of reaming engaged in care.
The reduction in LTP over time could also be attrib-
uted to the change in WHO guidelines [14] and the rec-
ommendation to start ART at higher CD4 counts (from
200 to 350 cell/μL) since patients who don’t receive im-
mediately ART are at risk of getting LTP; in our program
we recently (August 2014) lifted the threshold to 500
cell/μL and this could potentially lead to an increase in
program retention rates.
One potential limitation of our results could be due to
the likelihood of differential lost to follow-up long the
years, which can lead to difficulties in the classifications
of patients along the cascade and a potential for bias in
the estimates of risk factors. Overall, we feel that our re-
sults are generable to similar settings.
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